KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Revenue (2020 - 2025)

Recursion Pharmaceuticals' Revenue history spans 6 years, with the latest figure at $35.5 million for Q4 2025.

  • For Q4 2025, Revenue rose 681.74% year-over-year to $35.5 million; the TTM value through Dec 2025 reached $74.7 million, up 26.92%, while the annual FY2025 figure was $74.7 million, 26.92% up from the prior year.
  • Revenue reached $35.5 million in Q4 2025 per RXRX's latest filing, up from $5.2 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $35.5 million in Q4 2025 to a low of $2.5 million in Q4 2021.
  • Average Revenue over 5 years is $11.4 million, with a median of $11.0 million recorded in 2023.
  • Peak YoY movement for Revenue: soared 4170.0% in 2021, then crashed 80.16% in 2025.
  • A 5-year view of Revenue shows it stood at $2.5 million in 2021, then surged by 439.91% to $13.7 million in 2022, then fell by 20.36% to $10.9 million in 2023, then tumbled by 58.26% to $4.5 million in 2024, then skyrocketed by 681.74% to $35.5 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Revenue are $35.5 million (Q4 2025), $5.2 million (Q3 2025), and $19.2 million (Q2 2025).